Bystolic Advisory Committee: Trial Shortcomings Could Mean Tough Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Single pivotal trail for Forest's beta blocker may produce a skeptical audience on Jan. 11, when an FDA advisory committee evaluates the additional requested indication for chronic heart failure.